Tuesday, May 30, 2023


Biotechnology News Magazine


Airway Therapeutics Completes Dose Escalation in Phase 1b Trial of Zelpultide Alfa (AT-100) for Very Preterm Infants at Risk for Bronchopulmonary Dysplasia

Airway Therapeutics began recruiting patients on March 28, 2023, for daily treatment up to 7 days at the highest dose of zelpultide alfa (rhSP-D) following a Data Safety Monitoring Committee (DSMC) report of no safety concerns.

Roche introduces navify® Algorithm Suite, a digital library of medical algorithms that enhances clinical decision-making to optimise patient care

At the global HIMSS1 Conference, Roche showcases navify Algorithm Suite, a single platform offering clinicians access to medical algorithms generating insights to help improve care decisions.

DTCFF – RETRANSMISSION: Defence Breakthrough: Successfully Engineered Accum(TM)-mRNA Vaccine Creating a New Vaccine Platform. The in vivo Accum(TM)-mRNA Cancer Vaccine Program Begins

"The Defence Accum-mRNA vaccine program is on schedule. With this engineering steps completed, we are now initiating in vivo studies to compare the immunogenicity of the vaccine. The potency of the AccumTM-mRNA vaccine will be tested in animals on cancer solid T-cell lymphoma first, then subsequently on additional cancer solid tumors," says Mr. Plouffe, CEO of Defence Therapeutics.

Ginkgo Bioworks Announces Pathogen Monitoring Program at Kigali International Airport

Gingo Bioworks notes the program establishes a new node in a global early warning network for emerging variants to support timely and targeted public health response

DocSun Biomedical Limited Completes Technology Transfer to Future Now Biotech LLC

"We are thrilled to be transferring our tech and IPs to Future Now," said Mike Chen, CEO of DocSun Biomedical. "Our two companies share a common goal of improving healthcare and advancing medical technology, and this transfer will allow us to continue our mission on a larger scale."

Dotmatics Scientific R&D Platform Introduces Built-in GraphPad Prism Integrations

Users can create Prism templates with preset analyses and graphs, making it easier to export data from Dotmatics ELN and screening tools using a standardized method. This integration provides scientists with an easy-to-use, reproducible, no-code method to create publication-quality graphs notes Dotmatics.